Minerva Neurosciences posted a net loss of $3.26 million in Q2 2025, driven by lower spending as the company evaluates strategic alternatives following FDA's requirement for a confirmatory study of roluperidone.

Minerva Neurosciences reported a net loss of $3.8 million for the first quarter of 2025, a significant improvement compared to the $8.6 million net loss in the same period last year. The decrease in net loss was primarily driven by lower research and development expenses and the absence of non-cash interest expense related to the sale of future royalties. The company continues to engage with the FDA regarding the Complete Response Letter for roluperidone.